# A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

> **NCT04657289** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 451 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration (nAMD)

## Interventions

- **DRUG:** Ranibizumab
- **DEVICE:** Port Delivery System with Ranibizumab

## Key facts

- **NCT ID:** NCT04657289
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-07-14
- **Primary completion:** 2027-01-28
- **Final completion:** 2027-01-28
- **Target enrollment:** 451 (ACTUAL)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04657289

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04657289, "A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04657289. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*